» Articles » PMID: 32118734

Overexpression of MiR-17 is Correlated with Liver Metastasis in Colorectal Cancer

Overview
Specialty General Medicine
Date 2020 Mar 3
PMID 32118734
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in men and women. The presence of systemic disease, with metastatic spread to distant sites such as the liver, considerably reduces the survival rate in CRC. Cancer stem cells contribute to the metastatic potential of CRC. However, the mechanism underlying metastasis in CRC remains unclear. Thus, this study aimed to examine the expression of microRNAs (miRNAs) in CRC stem cells in cases of liver metastases and assess their correlation with clinicopathological features.

Methods: miRNAs showing high expression in liver metastases and primary lesions were selected through data mining of gene expression omnibus datasets, and miRNAs characteristic of stem cells were selected through COREMINE medical text mining. Subsequently, paired formalin-fixed paraffin-embedded tissue samples of primary CRC and liver metastasis from 30 patients were examined for the expression of miRNAs common to these lists (hsa-miR-20a, hsa-miR-26b, hsa-miR-146a, hsa-miR-17, hsa-miR-451, hsa-miR-23a, and hsa-miR-29a) using quantitative real-time polymerase chain reaction. Further, miRNA expression was compared between liver metastases and the primary tumor in each patient and the factors associated with differential expression were analyzed.

Results: hsa-miR-17 was significantly upregulated in liver metastases (P < .05), but no significant difference in the expression of hsa-miR-26b, hsa-miR-146a, hsa-miR-451, hsa-miR-23a, and hsa-miR-29a was observed between primary tumors and liver metastases. The higher expression of hsa-miR-17 in liver metastases was associated with the administration of neoadjuvant chemotherapy and tumor differentiation (P < .05) but was not associated with age, sex, tumor location, or lymphatic metastasis.

Conclusions: High expression of miR-17 may contribute to liver metastasis in CRC. Therefore, an in-depth understanding of its downstream pathways could help in elucidating the mechanisms underlying liver metastases in CRC. However, additional studies are warranted to validate these findings.

Citing Articles

Unraveling the Multifaceted Role of the miR-17-92 Cluster in Colorectal Cancer: From Mechanisms to Biomarker Potential.

Al-Nakhle H Curr Issues Mol Biol. 2024; 46(3):1832-1850.

PMID: 38534736 PMC: 10969598. DOI: 10.3390/cimb46030120.


A deep learning model predicts the presence of diverse cancer types using circulating tumor cells.

Albaradei S, Alganmi N, Albaradie A, Alharbi E, Motwalli O, A Thafar M Sci Rep. 2023; 13(1):21114.

PMID: 38036622 PMC: 10689793. DOI: 10.1038/s41598-023-47805-2.


Epigenetic and metabolic reprogramming in inflammatory bowel diseases: diagnostic and prognostic biomarkers in colorectal cancer.

Zayeri Z, Parsi A, Shahrabi S, Kargar M, Davari N, Saki N Cancer Cell Int. 2023; 23(1):264.

PMID: 37936149 PMC: 10631091. DOI: 10.1186/s12935-023-03117-z.


Construction of a prognostic signature associated with liver metastases for prognosis and immune response prediction in colorectal cancer.

Liu C, Lu Z, Yan J, Xue D, He X, Huang W Front Oncol. 2023; 13:1234045.

PMID: 37564935 PMC: 10411999. DOI: 10.3389/fonc.2023.1234045.


Multi-Omics Analysis of the Tumor Microenvironment in Liver Metastasis of Colorectal Cancer Identified FJX1 as a Novel Biomarker.

Zou J, Zhang H, Huang Y, Xu W, Huang Y, Zuo S Front Genet. 2022; 13:960954.

PMID: 35928453 PMC: 9343787. DOI: 10.3389/fgene.2022.960954.


References
1.
Jin Y, Wang M, Hu H, Huang Q, Chen Y, Wang G . Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. Int J Biol Macromol. 2018; 117:445-453. DOI: 10.1016/j.ijbiomac.2018.05.151. View

2.
Liu X, Zhang A, Xiang J, Lv Y, Zhang X . miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep. 2016; 36(3):1385-92. DOI: 10.3892/or.2016.4971. View

3.
Zhou P, Ma L, Zhou J, Jiang M, Rao E, Zhao Y . miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int J Oncol. 2016; 48(4):1737-48. DOI: 10.3892/ijo.2016.3392. View

4.
Shen Y, Gong J, Zhou L, Sheng J . MiR-451 as a new tumor marker for gastric cancer. Oncotarget. 2017; 8(34):56542-56545. PMC: 5593581. DOI: 10.18632/oncotarget.17239. View

5.
Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View